Tango Therapeutics, Inc. — Director's Dealing 2021

Nov 3, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Tango Therapeutics, Inc. (TNGX)
CIK: 0001819133
Period of Report: 2021-11-01

Reporting Person: Rudoltz Marc (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-01	Stock Option (Right to Buy)	$12.91	A	350000	Acquired	2031-11-01	Common Stock (350000)	Direct

Footnotes

F1: This option shall vest and become exercisable over a four-year period, at a rate of 25% on October 18, 2022, with the remaining option shares vesting in 36 equal monthly installments thereafter.